바이러스 백신 CDMO 시장 : 규모, 점유율, 동향 분석, 유형별, 서비스별, 워크플로우별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Viral Vaccines CDMO Market Summary

The global viral vaccines CDMO market size was estimated at USD 2.23 billion in 2024 and is projected to reach USD 7.39 billion by 2033, growing at a CAGR of 15.1% from 2025 to 2033. The growth of the market is mainly due rising demand for outsourced manufacturing of viral vaccines, driven by increased prevalence of infectious diseases, growing adoption of viral vector-based platforms for both prophylactic and therapeutic use, and the need for rapid, scalable production solutions.

Furthermore,the increasing prevalence of viral illnesses such as influenza, human papillomavirus (HPV), hepatitis, and emerging threats like dengue, RSV, and viral hemorrhagic fevers has pushed public and private vaccine developers to accelerate production timelines. Given the high biosafety, quality, and process control requirements associated with live-attenuated, inactivated, and recombinant viral vaccines, pharmaceutical companies are increasingly turning to CDMOs with established viral platforms, BSL-2/3 containment infrastructure, and end-to-end compliance capabilities. Moreover, post-COVID-19, governments and global health agencies have significantly increased funding and long-term procurement agreements for pandemic preparedness, which has increased demand for scalable viral vaccine production. CDMOs offer specialized knowledge in viral seed banking, cell line development, vector engineering, and cGMP-grade virus production, enabling vaccine innovators to shorten development timelines and meet regulatory milestones with lower operational risk.

The growing adoption of single-use bioreactors, modular cleanrooms, and high-speed fill-finish lines including prefilled syringes and lyophilized vials has made outsourcing an efficient alternative for both small biotech firms and large vaccine players. Additionally, as several developers seek to expand into global markets, CDMOs with multi-regional regulatory compliance such as U.S. FDA, EMA, WHO PQ and distributed manufacturing footprints are favored for commercial supply contracts. Further, the rise of viral vector technologies in gene therapy and oncology has also unclear the lines between traditional vaccines and therapeutic platforms, increasing cross-application demand for viral CDMO services. As biologics become more personalized and technically complex, companies like Lonza, Fujifilm Diosynth, Samsung Biologics, and WuXi Biologics are scaling both upstream viral production and downstream sterile fill-finish capacities, positioning themselves as strategic manufacturing partners in the next era of global viral vaccine development.

Global Viral Vaccines CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2033. For this study, Grand View Research has segmented the global viral vaccines CDMO market report based on type, workflow, service, end use, and region.

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Attenuated Vaccine
• Inactivated Vaccine
• DNA Vaccines
• Subunit Vaccines
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical
• Commercial
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Formulation & Process Development
  • Upstream Development
  • Downstream Development
• Analytical Testing
• Fill-Finish Services
• Packaging & Labeling
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical Companies
• Academic and Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Value chain based analysis (Model 2)
  • 1.7.3. Multivariate Analysis (Model 3)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Industry Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Viral Vaccines CDMO Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Viral Vaccines CDMO Market; Type Movement Analysis
• 4.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
• 4.4. Attenuated Vaccine
  • 4.4.1. Attenuated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Inactivated Vaccine
  • 4.5.1. Inactivated Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. DNA Vaccines
  • 4.6.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Subunit Vaccines
  • 4.7.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Viral Vaccines CDMO Market: Service Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Viral Vaccines CDMO Market; Service Movement Analysis
• 5.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
• 5.4. Formulation & Process Development
  • 5.4.1. Formulation & Process Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Upstream Development
    • 5.4.2.1. Upstream Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Downstream Development
    • 5.4.3.1. Downstream development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Analytical Testing
  • 5.5.1. Analytical Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Fill-Finish Services
  • 5.6.1. Fill-Finish Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Packaging & Labeling
  • 5.7.1. Packaging & Labeling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Viral Vaccines CDMO Market: Workflow Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Viral Vaccines CDMO Market; Workflow Movement Analysis
• 6.3. Viral Vaccines CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)
• 6.4. Clinical
  • 6.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Commercial
  • 6.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Viral Vaccines CDMO Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Viral Vaccines CDMO Market; End Use Movement Analysis
• 7.3. Viral Vaccines CDMO Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
• 7.4. Biopharmaceutical Companies
  • 7.4.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Academic and Research Institutes
  • 7.5.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Regional Dashboard
• 8.2. Global Viral Vaccines CDMO Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
• 8.3. North America
  • 8.3.1. North America Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S.
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Germany Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. UK
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. UK Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. South Korea Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Australia
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Australia Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Thailand
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Thailand Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Viral Vaccines CDMO Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Company Market Assessment Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. Lonza
    • 9.3.1.1. Company overview
    • 9.3.1.2. Financial performance
    • 9.3.1.3. Service benchmarking
    • 9.3.1.4. Strategic initiatives
  • 9.3.2. Catalent Pharma
    • 9.3.2.1. Company overview
    • 9.3.2.2. Financial performance
    • 9.3.2.3. Service benchmarking
    • 9.3.2.4. Strategic initiatives
  • 9.3.3. Thermo Fisher Scientific
    • 9.3.3.1. Company overview
    • 9.3.3.2. Financial performance
    • 9.3.3.3. Service benchmarking
    • 9.3.3.4. Strategic initiatives
  • 9.3.4. Samsung Biologics
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Service benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. Fujifilm Diosynth Biotechnologies
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Service benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. WuXi Biologics
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Service benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. Recipharm AB.
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Service benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. HALIX B.V
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Service benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. Batavia Biosciences B.V
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Service benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. Alcami Corporation
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Service benchmarking
    • 9.3.10.4. Strategic initiatives